Keppra pediatric dose

5 Pediatric Labeling Keppra (Levetiracetam XR tablets) Adult approval: Septem Pediatric labeling: Aug Pediatric Use:

The treatment dose was reduced in 0.8% of adult patients treated with immediate-release KEPPRA, compared to 0.5% of placebo-treated patients. Overall, 11% of pediatric patients treated with immediate-release KEPPRA experienced behavioral symptoms associated with discontinuation or dose reduction, compared to 6.2% of placebo-treated pediatric

Levetiracetam. Contents. 1 General; 2 Adult Dosing; 3 Pediatric Common Trade Names: Keppra. Adult Dosing. Status Epilepticus. mg

by S Mehrotra Cited by 9Levetiracetam (Keppra). ≥ 1 month. Acts by binding to SV2A protein Dose in pediatrics was selected such that it produces plasma

demonstrated pediatric-specific problems that would phenytoin was administered over a to first-dose administration. has been mL/minute/1. KEPPRA XR dosing

KEPPRA as adjunctive therapy in 98 (KEPPRA N=64, placebo N=34) pediatric levels achieved within the therapeutic dose range, are neither inhibitors

and efficacy of KEPPRA in pediatric patients has not been established; therefore, Health Canada has not therapeutic dose of KEPPRA (500 mg bid)

The maximum daily dose was 3000 mg/day. For KEPPRA tablet dosing in pediatric patients weighing 20 to 40 kg, initiate treatment with a daily dose of 500 mg

Pediatric Patients When using KEPPRA injection for pediatric patients, dosing is weight-based (mg per kg).